Teva sues Corcept over alleged mifepristone market monopoly, Reuters says

Teva (TEVA) is suing Corcept Therapeutics (CORT) in federal court in San Francisco, claiming that the rival drugmaker monopolizes the market for mifepristone-based Korlym, which is used to treat Cushing’s syndrome, Reuters’ Mike Scarcella reports. The suit claims that Corcept and Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn,” the author says. Teva alleges that Corcept pays “bribes and kickbacks” to physicians to keep them prescribing brand Korlym, whose active ingredient is mifepristone, the author notes.